A Study to Investigate the Safety and Tolerability of CAN10 Antibody in Healthy Subjects and in Subjects With Plaque Psoriasis.

NCT ID: NCT06143371

Last Updated: 2023-12-01

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-08-21
• Study Completion Date: 2025-04-24

Brief Summary

This is a first-in-human, randomized, double- blind, placebo-controlled, dose escalation study to investigate how different doses of CAN10 are tolerated, taken up by the body and how long CAN10 stays in the body. In the first part of the study, the single ascending dose (SAD) cohorts, CAN10 will be given as a single intravenous dose to healthy subjects. In the second part of the study, the multiple ascending dose (MAD) cohorts, CAN10 will be given as repeated subcutaneous doses to participants with mild to moderate plaque psoriasis.

Conditions

Healthy; Plaque Psoriasis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

CAN10 single ascending dose

A single dose of CAN10 will be administered intravenously (IV) to healthy subjects.

Group Type: EXPERIMENTAL

CAN10

Intervention Type: BIOLOGICAL

Single dose intravenous or Multiple doses subcutaneously

CAN10 single ascending dose - placebo

A single dose of matching placebo will be administered intravenously (IV) to healthy subjects.

Group Type: PLACEBO_COMPARATOR

CAN10 - Placebo

Intervention Type: BIOLOGICAL

Single dose intravenous or Multiple doses subcutaneously

CAN10 multiple ascending dose

Multiple doses of CAN10 will be administered subcutaneously (SC) to subjects with mild to moderate plaque psoriasis

Group Type: EXPERIMENTAL

CAN10

Intervention Type: BIOLOGICAL

Single dose intravenous or Multiple doses subcutaneously

CAN10 multiple ascending dose - placebo

Multiple doses of matching placebo will be administered subcutaneously (SC) to subjects with mild to moderate plaque psoriasis

Group Type: PLACEBO_COMPARATOR

CAN10 - Placebo

Intervention Type: BIOLOGICAL

Single dose intravenous or Multiple doses subcutaneously

Interventions

CAN10

Single dose intravenous or Multiple doses subcutaneously

Intervention Type: BIOLOGICAL

CAN10 - Placebo

Single dose intravenous or Multiple doses subcutaneously

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Male or female, aged 18 to 50 years of age (inclusive) at the time of signing informed consent.
• Body mass index (BMI) 18 to 30 kg/m2 (inclusive) and a weight between 50 to 100 kg (inclusive) at the time of screening
• Considered by the investigator to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead ECG results, and physical examination findings at screening.
• Female subjects of childbearing potential must use a highly effective method of birth control and have a negative pregnancy test at screening and before the first dose of study drug. Male subjects with female partners must agree to use a condom, and their female partners are recommended to use a highly effective method of birth control.

Additionally for subjects with plaque psoriasis only:

• A diagnosis of plaque psoriasis with Psoriasis Area Severity Index (PASI) score ≥3 to ≤15 and Physician Global Assessment (PGA) score ≥2 (mild) to <4 (moderate).
• No disease manifestation requiring systemic immunosuppressive therapy.

Exclusion Criteria

• History or presence of:

1. Severe allergy/hypersensitivity (subjects with mild pollen allergy can be included).

2. Significant kidney, liver, or urologic disease.

3. Clinically significant psychiatric disorders

4. Tuberculosis (TB) infection or positive QuantiFERON TB Gold test

5. Any other clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.

• Clinically significant illness, medical/surgical procedure, or trauma within 4 weeks before the first dose of study drug.
• Ongoing opportunistic or systemic infections
• A positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus antigen or antibodies at screening.

Additionally for subjects with plaque psoriasis only:

• Psoriasis other than a plaque variant.
• Any sign of infection of any of the psoriatic lesions.
• Use of any of the following treatments within the indicated washout period before the first dose of study drug:

1. 12 weeks or 5 half-lives (whichever is longer) for biologic agents known or expected to impact the course of psoriasis or its assessments.

2. 12 weeks for oral retinoids

3. 8 weeks for cyclosporin, interferon, methotrexate, other systemic immunosuppressive or immunomodulating agents, or psoralen plus ultraviolet A (UVA)

4. 2 weeks for immunizations or drugs known to possibly worsen psoriasis, unless on a stable dose for >12 weeks

5. 1 week for topical treatments: corticosteroids, immunomodulators, anthralin (dithranol), Vitamin D derivatives, retinoids, or coal tar (used on the body)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Cantargia AB

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Manuela Casjens, MD

Role: PRINCIPAL_INVESTIGATOR

CRS Clinical Research Services Berlin GmbH

Locations

CRS Clinical Research Services Berlin GmbH

Berlin, , Germany

Site Status: RECRUITING

Countries

Germany

Central Contacts

CANTARGIA AB

Role: CONTACT

Phone: +46 46 2756260

Email: clinicaltrials@cantargia.com

Facility Contacts

Manuela Casjens, MD

Role: primary

References

Mulholland M, Depuydt MAC, Jakobsson G, Ljungcrantz I, Grentzmann A, To F, Bengtsson E, Jaensson Gyllenback E, Gronberg C, Rattik S, Liberg D, Schiopu A, Bjorkbacka H, Kuiper J, Bot I, Slutter B, Engelbertsen D. Interleukin-1 receptor accessory protein blockade limits the development of atherosclerosis and reduces plaque inflammation. Cardiovasc Res. 2024 May 7;120(6):581-595. doi: 10.1093/cvr/cvae046.

Reference Type: DERIVED

PMID: 38563353 (View on PubMed)

Other Identifiers

2023-504450-35

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

CAN10CLIN001

Identifier Type: -

Identifier Source: org_study_id